Key facts
- Mikrobiomik’s last known valuation is $16.7M.
- It has raised $10.3M; the latest was Equity Crowdfunding ($710K) in Sep 2025.
- Notable investors include Seed Capital Bizkaia, Basque Government, San Ignacio SL, Ekintzaile, Government of Spain — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Mikrobiomik
- ·The full record, as it builds
Funding rounds
No funding rounds for Mikrobiomik are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mikrobiomik
Operator of a biopharmaceutical company intended to research, develop, produce, and market biological drugs based on the human microbiome. The company's biological medicine treats both the primary episode and recurrence of Clostridium difficile infection with the administration of 4 capsules with full-spectrum and purified intestinal microbiota technology as a single dose, enabling patients to receive treatments based on human microbiota.
- Sector
- Healthcare
- HQ
- Bilbao, Spain
- Founded
- 2018
- Employees
- 21
- Website
- mikrobiomik.net/
- Ownership
- Privately Held (backing)
Mikrobiomik doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mikrobiomik shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mikrobiomik in its N-PORT filings yet. We sweep new filings monthly.